By Tiziana Celine Tech Times

Doctors are hoping stem cell therapy may be a weapon in the fight against coronavirus. Regenerative medicine employer Mesoblast introduced a 300-person trial on Friday, Apr. 24, to decide whether or not stem cell treatments will work in COVID-19 patients tormented by severe lung inflammation.

The treatments had been intravenous infusions of Ryoncil (remestemcel-L) by Mesoblast Limited in Australia and the United States. Ryoncil, under a priority review by the FDA, is also under development for other uncommon sicknesses and inflammatory conditions, according to the agency’s statement.

ALSO READ: Two Stem Cell Transplants May Increase Survival Chances Of Kids With Neuroblastoma